

DOCON TECHNOLOGIES PRIVATE LIMITED

March 31, 2026

To, National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400051	To, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001
To, Thyrocare Technologies Limited D37/3, TTC MIDC, Turbhe, Navi Mumbai – 400073	

Sub: Update to earlier disclosures under Regulation 31 of SEBI (SAST) Regulations, 2011 in respect of encumbrance on shares of Thyrocare Technologies Limited – Partial redemption of Series 1 Non-Convertible Debentures through reduction of face value

Dear Sir & Madam,

We refer to our earlier disclosures dated September 24, 2025, November 11, 2025 and December 05, 2025, made under Regulation 31 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (“SEBI SAST Regulations”), in respect of the encumbrance created by Docon Technologies Private Limited (“Docon”), Promoter of Thyrocare Technologies Limited (“the Company”), in favour of Catalyst Trusteeship Limited, acting as Debenture Trustee for the Non-Convertible Debentures (“NCDs”) issued by API Holdings Limited, the holding company of Docon.

Please note that API Holdings Limited has **partially redeemed its Series 1 Non-Convertible Debentures aggregating to INR 1,200 million (Rupees One Thousand Two Hundred Million only)** on March 30, 2026, through reduction of face value per debenture from INR 10,00,000 to INR 9,00,000 per debenture.

Pursuant to the aforesaid, there is **no change in the number of encumbered shares of Thyrocare Technologies Limited held by Docon**. However, certain details last disclosed on December 05, 2025 (including outstanding principal amount and particulars of the debenture holders) have been updated to reflect the current position.

The updated details are enclosed in **Annexure 1** in the format prescribed under the Regulation 31 of the SEBI SAST Regulations.

You are requested to take the same on record.

For Docon Technologies Private Limited


Madhuri Sudhir Sarangdhar
Company Secretary



Encl: **Annexure 1**

DOCON TECHNOLOGIES PRIVATE LIMITED

Annexure 1

Format for disclosure by the Promoter(s) to the stock exchanges and to the Target Company for encumbrance of shares / invocation of encumbrance/ release of encumbrance, in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 – Annexure 1

Name of the Target Company (TC)					Thyrocare Technologies Limited (“Thyrocare”)								
Names of the stock exchanges where the shares of the target company are listed					1. BSE Limited 2. National Stock Exchange of India Limited								
Date of reporting					March 31, 2026								
Name of the promoter or PAC on whose shares encumbrance has been created/released/invoked					Promoter: Docon Technologies Private Limited PAC: API Holdings Limited								
Details of the creation of encumbrance													
Name of the promoter(s) or PACs with him*	Promoter holding in the target company (1)		Promoter holding already encumbered (2)		Details of events pertaining to encumbrance (3)							Post event holding of Encumbered shares {creation [(2)+(3)] / release [(2)-(3)] / invocation [(1)-(3)]}	
	Number	% of total share capital	Number	% of total share capital	Type of event (creation /Release /invocation)	Date of creation /release/ invocation of encumbrance	Type of encumbrance (pledge/ line/ non disposal undertaking / others)	Reasons for encumbrance **	Number	% of share capital	Name of the entity in whose favor shares Encumbered ***	Number	% of total share capital
Docon Technologi	9,69,69,696	60.93	9,69,69,696	60.93	Update to earlier disclosures	API Holdings Limited	Others* * API Holdings	The encumbrance on	9,69,69,696	60.93	The Shares has been pledged with Catalyst Trusteeship Limited as	9,69,69,696	60.93



DOCON TECHNOLOGIES PRIVATE LIMITED

es Private Limited ("Docon")					under Regulation 31 of the SEBI (SAST) Regulations, 2011 in respect of encumbrance on shares of Thyrocare Technologies Limited – partial redemption of Series 1 non-convertible debentures through reduction of face value	has partially redeemed its Series 1 Non-Convertible Debentures aggregating to INR 1,200 million (Rupees One Thousand Two Hundred Million only) on March 30, 2026.	Limited has partially redeemed its Series 1 Non-Convertible Debentures aggregating to INR 1,200 million (Rupees One Thousand Two Hundred Million only) on March 30, 2026, through reduction of face value per debenture from INR 10,00,000 to INR	shares has been created pursuant to a corporate guarantee extended by Docon Technologies Private Limited ("Docon") to secure the obligations of API Holdings Limited ("API"), the holding company, in respect of facilities availed by API through issuance of unlisted, secured, redeemabl			Debenture Trustee for Debenture issued by API. Details of Debenture Issued by API: 12,000 (Twelve Thousand) unlisted, unrated, secured, redeemable, non-convertible debentures, pursuant to partial redemption (first tranche) the face value stands reduced from INR 10,00,000 to INR 9,00,000 per debenture, aggregating to a nominal value of INR 10,800 million (Indian Rupees Ten Thousand Eight Hundred Million only) ("Series 1 Debentures"). Details of Debenture Holders/Investors for Series 1 Debenture: <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 10px;"> <thead> <tr> <th style="width: 70%;">Name</th> <th style="width: 30%;">Amount (in Million)</th> </tr> </thead> <tbody> <tr> <td>360 One Prime Limited</td> <td style="text-align: right;">2,497.50</td> </tr> <tr> <td>Micro Labs Limited</td> <td style="text-align: right;">2,266.20</td> </tr> <tr> <td>Tata Capital Limited</td> <td style="text-align: right;">1,125.00</td> </tr> <tr> <td>360 One Commercial Yield Fund</td> <td style="text-align: right;">810.00</td> </tr> <tr> <td>360 One Real Assets Advantage Fund</td> <td style="text-align: right;">657.00</td> </tr> <tr> <td>J Kumar Infraprojects Limited</td> <td style="text-align: right;">540.00</td> </tr> <tr> <td>Bennett Coleman And Company Limited</td> <td style="text-align: right;">450.00</td> </tr> </tbody> </table>	Name	Amount (in Million)	360 One Prime Limited	2,497.50	Micro Labs Limited	2,266.20	Tata Capital Limited	1,125.00	360 One Commercial Yield Fund	810.00	360 One Real Assets Advantage Fund	657.00	J Kumar Infraprojects Limited	540.00	Bennett Coleman And Company Limited	450.00		
Name	Amount (in Million)																												
360 One Prime Limited	2,497.50																												
Micro Labs Limited	2,266.20																												
Tata Capital Limited	1,125.00																												
360 One Commercial Yield Fund	810.00																												
360 One Real Assets Advantage Fund	657.00																												
J Kumar Infraprojects Limited	540.00																												
Bennett Coleman And Company Limited	450.00																												



DOCON TECHNOLOGIES PRIVATE LIMITED


						9,00,000 per debenture.	e, non- convertible debentures			Mvs Ventures Private Limited	393.30		
										360 One Income Opportunities Fund - Series 3	306.00		
						Pursuant to the aforesaid, there is no change in the number of encumbe d shares of Thyrocare Technologi es Limited held by Docon Technologi es Private Limited. However, certain details last disclosed on December 05, 2025 (including outstandin	Further, API Holdings Limited has partially redeemed its Series 1 Non- Convertible Debentures aggregating to INR 1,200 million (Rupees One Thousand Two Hundred Million only) on March 30, 2026, through reduction of face			360 One Income Opportunities Fund - Series 6	306.00		
										Alkram Venture Private Limited	177.30		
										Prakash Kumar Guha	149.40		
										360 One Income Opportunities Fund - Series 7	135.00		
										Sak Industries Private Ltd	135.00		
										Niraj Intex Llp	135.00		
										360 One Wam Limited	108.90		
										Rajendrakumar Shivkishan Agrawal	90.00		
										Dayanidhi Maran	61.20		
										Ganesh Polychem Ltd	45.00		
										Warmond Fiduciary Services Limited	36.00		
										Advik Hi Tech Private Limited	30.60		
										Lake Chemicals P Ltd	30.60		
										Vara Future LLP	30.60		
										Medley Pharmaceuticals Limited	30.60		
										Teritex Knitting Industries Private Limited	30.60		




DOCON TECHNOLOGIES PRIVATE LIMITED

								on December 05, 2025 (including outstandin g principal amount and particulars of the debenture holders) have been updated through this disclosure to reflect the current position.				
--	--	--	--	--	--	--	--	---	--	--	--	--

For and on behalf of Docon Technologies Private Limited


Madhuri Sudhir Sarangdhar
Company Secretary
Date: March 31, 2026



(**) The names of all the promoters, their shareholding in the target company and their pledged shareholding as on the reporting date should appear in the table irrespective of whether they are reporting on the date of event or not.
(*) Total share capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement. Diluted share / voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities / warrants into equity shares of the TC.